Endocrine resistance remains a key challenge in ER+/HER2- metastatic breast cancer, often driven by acquired ESR1 mutations. Early detection using ctDNA-based testing is essential for optimal integration of next-generation oral selective estrogen receptor degraders (SERDs). Watch this on-demand webcast from a previous live webinar as an expert oncologist and pathologist explore practical strategies for navigating ESR1 mutation-driven endocrine resistance in ER+/HER2- breast cancer. Case-based discussions feature: Optimizing ctDNA testing and ESR1 mutation monitoring within clinical workflows to inform treatment decisions Examining the evolving clinical evidence supporting next-generation SERD use Expert insights for timely sequencing of oral SERDs within the evolving treatment landscape. Don’t miss this opportunity to learn from experts and access downloadable reference slides to support decision-making for patients with endocrine-resistant, ESR1-mutated metastatic breast cancer.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 360 Park Avenue South
Pricing
99% of listed courses are free
298 of a sample of 300 are free · 416 courses listed here.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Operative Anesthesia
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Interventional Radiology
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Musculoskeletal Oncology
- Nephrology
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Hematology-Oncology
- Pediatric Neurology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Regional Anesthesia & Acute Pain
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Case-based learning
- includes Article / monograph / reference
- includes On-demand / recorded video
- Credit · Up to 0.5 credits
- MOC · Up to 0.5 points
- Commercial Support
-
ReleasedMay 8, 2026
-
Last day to claim creditMay 8, 2027 7 months left
-
eMedEd Genetic Predisposition for Breast Cancer & Management of BRCA1/2 Mutation Carriers
-
Medscape, LLC ESR1 Mutation Testing in Breast Cancer: Setting the Standard for Personalized Oncology?
-
Partners for Advancing Clinical Education Personalizing EGFR Mutation Positive NSCLC Care: Strategies for the Advanced Practice Provider
-
PRIME Education, Inc. (PRIME®) Real-Time Circulating ctDNA Monitoring for ESR1 Mutations in ER+ Breast Cancer
-
PRIME Education, Inc. (PRIME®) Clinical Evidence at the Edge of Resistance: Next-Generation SERDs for ESR1-Mutated Breast Cancer
-
PRIME Education, Inc. (PRIME®) Ushering in a New Era: Integrating Oral SERDs Into Standard Care for ER-Positive Breast Cancer
